We propose to continue our studies to develop, validate and optimize our novel approach to high-efficiency extraction of nucleic acids from bacteria. Once this work is completed, DNA Genotek Kits are expected to have the following properties: relatively simple to use; applicable to high-throughput environments; efficient release of DNA from a wide variety of microorganisms; stabilize the profile of species in a sample by (i) stabilizing the released DNA at room temperature for extended periods of time and (ii) preventing overgrowth of microorganisms in collected samples.
Blue-O Technology Inc has identified five proprietary samples that may have antiviral activity, either in prevention or treatment of viral infections. The intern will determine the activity range and toxicity of each proprietary samples in mammalian cells and a mouse model. Once this has been determined, each proprietary sample will be tested for its ability to prevent or treat human immunodeficiency virus, herpes simplex virus, coxsackievirus, influenza and dengue virus.
The appearance of multidrug resistance of pathogens is challenging the researcher and industrial communities to develop more efficacious antimicrobial treatments. Blue-O Technology Incorporation (Blue-O Tech) has developed a novel formulation of medicine that accelerates the wound healing, while having an excellent antimicrobial strength over a broad spectrum of pathogens. The objectives of this study are to evaluate the cytotoxic effects, the immunological response, and the healing properties of this novel medicine prior to its marketing and commercialization.
Multiple antibiotic resistances have increased over the past decades, challenging our ability to treat bacterial infections and thwarting our ability to develop new antimicrobial agents. Many resistance genes have not evolved within the pathogenic isolates but were acquired by lateral transfer. We recently showed that genes conferring glycopeptide resistance are highly prevalent in the human flora. Some of these genes are present in novel commensal anaerobic species of the gut suggesting that these bacteria may serve as a reservoir for resistance genes.
IMV has developed a novel depot-based vaccine platform that can be used with a variety of antigens and adjuvants, which can exhibit rapid and enhanced immune responses following a single dosage. This project will use cell tracking via molecular MRI to explore the immune cell migration in real time in an animal model of cancer, which in turn, will affect cancer growth. The novel application of molecular MRI to track regulatory T cells and effecter cells in a tumor challenge model will yield important information on such regulatory processes.